Study: Kre-Alkalyn® Compared to Creatine In Olympic Weightlifters

Science For Humans #1734: Dr. Jeff's Leg Workout
Science For Humans #1734: Dr. Jeff’s Leg Workout
October 7, 2015
Science For Humans #1738: Type 2 Diabetes For Dummies
Science For Humans #1738: Type 2 Diabetes For Dummies
October 14, 2015
Show all

Study: Kre-Alkalyn® Compared to Creatine In Olympic Weightlifters

A Double-Blind Comparative Trial of Kre-Alkalyn to Creatine in Olympic Weightlifters

Dr. Jeff Golini, Dr. Kamen Stroychev and Dr. Neno Terziiski
All American Pharmaceutical, Billings, MT, and I.S. Greenberg Medical Center, Sofia, Bulgaria

Study Objectives

To compare the effects of Kre-Alkalyn® and creatine monohydrate on training induced changes in strength and body composition using Olympic-level weight lifters.

Patients and Methods

Twenty-four healthy men from the Bulgarian National Weightlifting team were randomly assigned to ingest  either, 10 capsules x 750 mg of Kre-Alkalyn® daily (Test group), or 10 capsules x 750 mg of creatine monohydrate (Control group), each day for a total of 60 days.  Body weight, muscular performance (snatch, clean and jerk, high snatch, back squat) were monitored and assessed. Lifts were performed at maximum resistance for 1 repetition. Measurements were taken on baseline day and every day throughout the study according to the study schedule. Each athlete was required to maintain their normal dietary habit and training patterns during the study.


The Kre-Alkalyn® – Test group showed an average increase in their performance level, over baseline, of 10.76% (in the snatch, clean and jerk, high snatch and back squat), compared to the Control group (8.39%, over baseline). The average increase in total lifts for the Kre-Alkalyn® – Test group was 28.25% over the Control group.

Summary and Conclusions

It is difficult for high-caliber Olympic-level athletes to achieve considerable improvements in their muscular performance in a short timeframe, such as a 60 day trial. However, the Kre-Alkalyn® group was able to achieve a slight, but significant, degree of improvement in their level of performance over the creatine monohydrate group, and without any untoward side effects from daily Kre-Alkalyn® administration.

Research Poster Presentation Image:

Dr. Jeff Golini
Dr. Jeff Golini
Dr. Jeff Golini is the Founder, CEO and Executive Scientist of All American Pharmaceutical. He holds numerous patents for innovative compounds such as, Kre-Alkalyn buffered creatine monohydrate, Karbolyn, the high-performance carbohydrate, and Kre-Celazine.

Comments are closed.